Psychedelic Drugs ‘Far Exceed’ Cannabis Investment Potential (CNBC)

Shark Tank's Kevin O'Leary, Wesana (WSNAF) CEO Daniel Carcillo and director at Mass General Hospital’s Center for the Neuroscience of Psychedelics Dr....
Ehave, Psychedelic Stock Review

Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company

WE LOOKED FAR AND WIDE TO FIND OUR FAVORITE What exactly is a favorite? First...

Huge News at Ehave Inc.(EHVVF), our Favorite Psychedelic.

We just finished compiling the 2021 Psychedelic Investor Guide and reviewed 44 companies - in all shapes and sizes. Excluding Johnson &...
ehave,

Telehealth: Contactless Health Screening from Ehave (EHVVF) and VastMinz.

Contactless Health Screening Ehave acquires License covering G-20 Countries for all Psychedelic use, AI-Powered Telehealth Technology To Capture Physiological...
Psychedelic Stock Review

Are Psychedelics the New Prozac?

Amidst a national epidemic of opioid abuse, and suicides the need for new therapeutics has gained greater urgency. In it's first step to...
cybin

Cybin (CLXPF CYBN) Gets $8.00 Price Target From H.C. Wainwright.

Advancing Multiple Psychedelics in Multiple Indications; Initiating With a Buy and $8 Price Target.

Atai Life Sciences (ATAI) Founder Christian Angermayer Interview.(VIDEO)

Best Psychedelic related interview we've seen yet. Christian states, "I think ultimately, the total addressable market is 100% of the world population!"

I Use Ketamine for Depression – Here’s How It Works.

FREETHINK: When first manufactured as an anesthetic for humans and animals in 1962, doctors had no intention of prescribing ketamine for depression....
Psychedelic Stock Review

Psychedelic Investor Conferences.

Not Quite as Popular as the Bitcoin 2021 Conference Attended by 12,000 - But Worth Considering!

Latest article

Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...